AC Immune (NASDAQ:ACIU) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of AC Immune (NASDAQ:ACIU) from a sell rating to a hold rating in a report issued on Saturday.

Several other research firms have also commented on ACIU. BTIG Research restated a “buy” rating and issued a $8.00 price target on shares of AC Immune in a report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.00.

AC Immune Stock Down 1.0%

Shares of ACIU opened at $2.93 on Friday. AC Immune has a fifty-two week low of $1.43 and a fifty-two week high of $4.00. The company’s fifty day moving average is $3.20 and its two-hundred day moving average is $2.97. The firm has a market cap of $294.20 million, a PE ratio of -3.49 and a beta of 1.66.

Institutional Trading of AC Immune

Several large investors have recently modified their holdings of ACIU. Assenagon Asset Management S.A. purchased a new stake in shares of AC Immune during the third quarter worth about $549,000. Marshall Wace LLP acquired a new stake in AC Immune during the 4th quarter valued at approximately $586,000. Acadian Asset Management LLC increased its holdings in AC Immune by 87.1% during the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after purchasing an additional 172,796 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of AC Immune by 20.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock valued at $670,000 after purchasing an additional 36,353 shares in the last quarter. Finally, Sei Investments Co. purchased a new position in shares of AC Immune during the 2nd quarter valued at approximately $51,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.